UTHR - United Therapeutics Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $653.00 DETAILS

Stock News

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast.

Oct 21, 2026 03:00 AM • businesswire.com

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi.

Oct 20, 2026 03:00 AM • businesswire.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Friday, October 16th. The shares were sold at an average price of $534.66, for a total value of $5,079,270.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company,

Oct 20, 2026 12:45 AM • defenseworld.net

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The phase 2, 16-week, double blind SUMMIT study will evaluate the safety and tolerability of treprostinil SMI in approximately 40 patie.

Oct 19, 2026 03:00 AM • businesswire.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $539.99, for a total transaction of $5,129,905.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company's

Oct 18, 2026 12:09 AM • defenseworld.net

United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172

Oct 18, 2026 12:09 AM • defenseworld.net

2,241 United Therapeutics Corporation $UTHR Shares Sold by First Citizens Bank & Trust Co.

First Citizens Bank and Trust Co. trimmed its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 59.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,522 shares of the biotechnology company's stock after selling

Oct 16, 2026 11:37 PM • defenseworld.net

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.

Oct 14, 2026 10:41 AM • zacks.com

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.

Oct 14, 2026 09:16 AM • proactiveinvestors.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).

Oct 14, 2026 08:40 AM • zacks.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.

Oct 14, 2026 07:05 AM • 247wallst.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Oct 14, 2026 05:56 AM • zacks.com

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.

Oct 14, 2026 04:57 AM • barrons.com

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoenix, Arizona. United Therapeutics will also sponsor and host Time to Look Closer: Emerging Data and Sc.

Oct 13, 2026 03:00 AM • businesswire.com

Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and United Therapeutics (NASDAQ: UTHR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Profitability This table compares Intellia Therapeutics and United

Oct 11, 2026 09:58 PM • defenseworld.net

United Therapeutics (NASDAQ:UTHR) CEO Sells $5,215,025.00 in Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $548.95, for a total value of $5,215,025.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the

Oct 11, 2026 01:39 AM • defenseworld.net

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Oct 09, 2026 05:55 AM • zacks.com

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

Oct 01, 2026 09:20 AM • zacks.com

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Oct 01, 2026 07:49 AM • benzinga.com

United Therapeutics Won Its Patent War and Liquidia Collapsed

A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.

Oct 01, 2026 07:07 AM • 247wallst.com